CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care
Patients presenting with hormone receptor-positive (HR(+) ), human epidermal growth factor receptor 2-negative (HER2(-) ) metastatic breast cancer (MBC) are usually treated with endocrine therapy (ET), except if there is a concern about endocrine resistance or a need to achieve rapid disease control due to visceral crisis. The combination of CDK4/6 inhibitor + ET has now replaced single-agent ET as the standard first-line treatment; and it can also be considered a standard option in the second-line setting. This review briefly summarizes recently reported efficacy findings from the key phase III clinical trials of CDK4/6 inhibitor + ET in patients with HR(+) /HER2(-) MBC, including evidence that adding a CDK4/6 inhibitor to ET improves overall survival and does so without reducing patients' quality of life. There is still much to learn regarding the use of CDK4/6 inhibitors and how they may be optimally integrated into clinical practice. In particular, there is a need for specific biomarkers that help predict the likelihood of response or resistance to CDK4/6 inhibitor therapy; and for data to guide treatment decisions when a patient's disease progresses on a CDK4/6 inhibitor.
|ISBN||1743-7563 (Electronic) 1743-7555 (Linking)|
|Authors||Hui, R.; de Boer, R.; Lim, E.; Yeo, B.; Lynch, J.|
|Responsible Garvan Author||Prof Elgene Lim|
|Publisher Name||Asia Pacific Journal of Clinical Oncology|
|Published Volume||17 Suppl 1|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/33506626|